Researchers at the University of Bayreuth and Forschungszentrum Jülich have demonstrated that specific light-sensitive ...

Scientists pieced together the genetic history of Acinetobacter baumannii — a notoriously stubborn hospital pathogen — using ...

ART5 is designed to address the most common root cause of ADPKD by targeting PKD1, potentially restoring PC1 production in approximately 85% of patientsFirst-in-human SAD study in healthy volunteers ...

What happens to the human body in space may help scientists create new anti-aging therapies. UCF's Michal Masternak and his ...

Initially, unadjusted analyses suggested a slight increase in the risk of MCI or dementia among hypnotic users compared with ...

Scientists have developed Spudcell, an advanced synthetic cell capable of adapting to its environment and learning survival skills, marking a breakthrough in synthetic biology.

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side ...

(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment ...

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast ...

In an interview, synthetic biologist Peter Carr explains research on synthetic cells, their potential benefits and hazards, ...

AVE has made a breakthrough with a phase III insomnia trial for its soft gel cannabidiol to manage sleeplessness. ... Read ...